Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Trikafta, a triple combination therapy for CF in patients with specific gene mutations, reaches endpoint in Phase III clinical trial The crisis of purchasing imported consumables in bulk in 10 provinc ...

Johnson & Johnson terminates global Phase III clinical trial of Stelara for the treatment of systemic lupus erythematosus Trikafta, a triple combination therapy for CF in patients with specific gene ...

INR:9523. newcastle horse racing tips today Is the Cold Winter of Private Medical Care Coming? In-depth Analysis of ...